Cytokinetics (CYTK) – Research Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of Cytokinetics (NASDAQ: CYTK) recently:

• 10/20/2026 – Cytokinetics was downgraded by Wall Street Zen from “hold” to “sell”.
• 10/19/2026 – Cytokinetics had its “buy” rating reaffirmed by HC Wainwright. They now have a $140.00 price target on the stock.
• 10/16/2026 – Cytokinetics is now covered by William Blair. They set an “outperform” rating on the stock.
• 10/15/2026 – Cytokinetics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/14/2026 – Cytokinetics had its “buy” rating reaffirmed by UBS Group. They now have a $104.00 price target on the stock.
• 10/12/2026 – Cytokinetics was upgraded by Wall Street Zen from “sell” to “hold”.
• 10/8/2026 – Cytokinetics had its price target raised by Royal Bank Of Canada from $112.00 to $113.00. They now have an “outperform” rating on the stock.
• 10/4/2026 – Cytokinetics was downgraded by Wall Street Zen from “hold” to “sell”.
• 9/26/2026 – Cytokinetics was upgraded by Wall Street Zen from “sell” to “hold”.
• 9/11/2026 – Cytokinetics had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 9/1/2026 – Cytokinetics was upgraded by Morgan Stanley from “overweight” to “buy”.
• 8/31/2026 – Cytokinetics had its “buy” rating reaffirmed by HC Wainwright. They now have a $140.00 price target on the stock.
• 8/29/2026 – Cytokinetics was downgraded by Wall Street Zen from “hold” to “sell”.

Insider Activity at Cytokinetics

In related news, Director B. Parshall sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $71.48, for a total value of $357,400.00. Following the sale, the director owned 10,784 shares in the company, valued at approximately $770,840.32. This trade represents a 31.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Andrew Callos sold 14,000 shares of Cytokinetics stock in a transaction that occurred on Thursday, July 30th. The stock was sold at an average price of $79.88, for a total transaction of $1,118,320.00. Following the completion of the sale, the executive vice president directly owned 58,555 shares of the company’s stock, valued at approximately $4,677,373.40. This trade represents a 19.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 183,926 shares of company stock valued at $12,937,330 over the last ninety days. Company insiders own 2.60% of the company’s stock.

Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering and developing medicines that target muscle function and contractility. The company applies muscle biology and sarcomere science to develop potential treatments for cardiovascular and neuromuscular diseases, including conditions in which impaired muscle performance contributes to disease progression.

Its leading investigational program is aficamten, a selective cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy and other potential cardiovascular indications.